Image

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

Investigational Treatment for Recurrent or Refractory Solid Tumors in Pediatric Patients

Recruiting
12-30 years
All
Phase 1/2
  • Simplified description (AI rewritten)
  • Technical description (Original)

This study investigates recurrent or refractory solid tumors, including lymphomas and desmoid tumors. The purpose of this study is to evaluate the investigational medication, tegavivint, in pediatric patients with these conditions.

The study focuses on evaluating the safety and possible benefits of tegavivint. It will assess how well patients tolerate the medication and its effects on tumor growth.

  • Who can participate: Children and young adults aged 12 months to 30 years with recurrent or refractory solid tumors can participate. Participants must have a verified diagnosis and meet specific health criteria.
  • Study details: Participants will receive the investigational medication through an IV infusion.
  • Study timelines and visits: The study will last 24 months. The study requires 26 visits.
Print
Study details
    Colorectal Carcinoma
    Endometrial Carcinoma
    Melanoma
    Neuroblastoma
    Ovarian Carcinoma
    Pancreatic Ductal Adenocarcinoma
    Recurrent Desmoid Fibromatosis
    Recurrent Ewing Sarcoma
    Recurrent Hepatoblastoma
    Recurrent Hepatocellular Carcinoma
    Recurrent Malignant Solid Neoplasm
    Recurrent Non-Hodgkin Lymphoma
    Recurrent Osteosarcoma
    Refractory Desmoid Fibromatosis
    Refractory Ewing Sarcoma
    Refractory Hepatoblastoma
    Refractory Hepatocellular Carcinoma
    Refractory Malignant Solid Neoplasm
    Refractory Non-Hodgkin Lymphoma
    Refractory Osteosarcoma
    Solid Pseudopapillary Neoplasm of the Pancreas
    Wilms Tumor

NCT04851119

Children's Oncology Group

29 August 2026

Contact a study center
Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.